IL-23 Antibody (brazikumab) [Allophycocyanin]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28743APC
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
ELISA, Flow Cytometry, Functional
Label
Allophycocyanin (Excitation = 620-650 nm, Emission = 660-670 nm)
Antibody Source
Recombinant Monoclonal Human IgG2 Clone # brazikumab
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for IL-23 Antibody (brazikumab) [Allophycocyanin]
Immunogen
IL-23
Clonality
Monoclonal
Host
Human
Isotype
IgG2
Applications for IL-23 Antibody (brazikumab) [Allophycocyanin]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: IL-23
Long Name
Interleukin 23
Alternate Names
IL-23 p19/IL-12 p40, IL-23p19/IL-12p40, IL23, SGRF
Gene Symbol
IL23A
Additional IL-23 Products
Product Documents for IL-23 Antibody (brazikumab) [Allophycocyanin]
Product Specific Notices for IL-23 Antibody (brazikumab) [Allophycocyanin]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...